Follow The Filings

RCUS Arcus Biosciences Inc.

Health Care, filed as ARCUS BIOSCIENCES INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 2.6%
  • $14M
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed Arcus Biosciences.

Who owns this now

Largest portfolio weights among holders, up to 2.6% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 2.6%

Who owns RCUS

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 2.6% Reduce −0.5% 441,829 $14M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RCUS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RCUS insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $8.4M sold by 4 insiders under 10b5-1 plans
  1. Alexander Azoy Chief Accounting Officer
    Planned sale
    $85K 2,827 shares at $30.00 6.7% of stake
    Traded Aug 21 Filed Aug 24
    ↗
  2. Juan C. Jaen President
    Planned sale
    $2M 68,569 shares at $29.63 7.7% of stake
    Traded Jul 9–10 Filed Jul 13
    ↗
  3. Juan C. Jaen President
    Planned sale
    $878K 31,431 shares at $27.92 3.4% of stake
    Traded Jun 22–24 Filed Jun 24
    ↗
  4. Alexander Azoy Chief Accounting Officer
    Planned sale
    $66K 2,562 shares at $25.77 6.1% of stake
    Traded Jun 1 Filed Jun 1
    ↗
  5. Robert C. Goeltz II CFO
    Planned sale
    $199K 7,763 shares at $25.63 8.4% of stake
    Traded May 11 Filed May 12
    ↗
  6. Juan C. Jaen President
    Planned sale
    $681K 31,823 shares at $21.41 3.3% of stake
    Traded Jan 5 Filed Jan 7
    ↗
  7. Robert C. Goeltz II CFO
    Planned sale
    $153K 6,552 shares at $23.38 8.8% of stake
    Traded Dec 31, 2025 Filed Jan 2
    ↗
  8. Alexander Azoy Chief Accounting Officer
    Planned sale
    $97K 4,343 shares at $22.25 19% of stake
    Traded Dec 18, 2025 Filed Dec 18, 2025
    ↗
  9. Juan C. Jaen President
    Planned sale
    $2.1M 82,997 shares at $24.71 8% of stake
    Traded Dec 4, 2025 Filed Dec 5, 2025
    ↗
  10. Alexander Azoy Chief Accounting Officer
    Planned sale
    $49K 1,900 shares at $26.00 6.5% of stake
    Traded Nov 26, 2025 Filed Dec 1, 2025
    ↗
  11. Robert C. Goeltz II CFO
    Planned sale
    $125K 5,000 shares at $25.00 5.4% of stake
    Traded Nov 26, 2025 Filed Nov 26, 2025
    ↗
  12. Juan C. Jaen President
    Planned sale
    $1M 50,000 shares at $20.26 4.6% of stake
    Traded Nov 17–18 Filed Nov 19, 2025
    ↗
  13. Jennifer Jarrett COO
    Planned sale
    $954K 50,291 shares at $18.97 19% of stake
    Traded Nov 7, 2025 Filed Nov 12, 2025
    ↗
  14. Juan C. Jaen President
    Planned sale
    $88K 4,314 shares at $20.32 0.4% of stake
    Traded Oct 30, 2025 Filed Nov 3, 2025
    ↗
  15. Juan C. Jaen President
    Planned sale
    $2M 96,859 shares at $20.76 8.2% of stake
    Traded Oct 28–29 Filed Oct 30, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 14 stock grants, 14 sales to cover taxes, 4 option exercises, and 3 gifts.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 2.02 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 7 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $117M $51M $33M
Net income -$307M -$283M -$353M
Net margin * -262.4% -554.9% -1069.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.831B $1.02B $1.01B
Total non-current assets * $264M $134M $132M
Total assets $1.1B $1.15B $1.14B
Total current liabilities $184M $226M $231M
Total equity $462M $485M $631M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$306M -$170M -$482M
Cash from investing $194M -$84M $66M
Cash from financing $33M $277M $488M
Net change in cash -$79M $23M $72M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.